| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.3 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.3 |